The use of longitudinal change in CANTAB-PAL, a cognitive test that is sensitive to early cognitive decline, was critical in the discovery of MAPKAPK5 as a potential biomarker relevant to AD. This evidence concerns the gene MAPKAPK5 and Alzheimer disease.